LEADER 03112nam 2200397 450 001 9910154921903321 005 20230808200613.0 010 $a1-78536-937-7 035 $a(CKB)3710000000954421 035 $a(MiAaPQ)EBC4749863 035 $a(EXLCZ)993710000000954421 100 $a20161212h20162016 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aAchieving proof of concept in drug discovery and development $ethe role of competition law in collaborations between public research organizations and industry /$fHelen Yu 210 1$aCheltenham, [England] ;$aNorthampton, Massachusetts :$cEdward Elgar Publishing,$d2016. 210 4$dİ2016 215 $a1 online resource (280 pages) 311 $a1-78536-938-5 320 $aIncludes bibliographical references and index. 327 $a. Introduction -- The pharmaceutical industry and drug development models -- Intellectual property rights and competition law in collaborative drug development between industry and integrated drug discovery organizations -- Application of competition law to the integrated drug discovery model: research and development block exemption regulation -- Application of competition law to the integrated drug discovery model: technology transfer block exemption regulation -- Analysis of collaboration agreements between integrated drug discovery organizations and industry -- 7. Conclusion and implications. 330 $aOne of the major shortcomings of the current drug discovery and development process is the inability to bridge the gap between early stage discoveries and pre-clinical research in order to advance innovations beyond the discovery phase. This book examines a drug discovery and development model, where the respective expertise of academia and industry are brought together to take promising discoveries through to proof of concept, providing a means to de-risk the drug discovery and development process. Expert author Helen Yu explores integrated drug discovery by analyzing the intersection of intellectual property law and competition law and discusses the role of stakeholders in the efficient translation and commercialization of publically funded research. Considering the transactional risks associated with drug discovery and development, this book advocates for a greater emphasis on contractual freedom and economic efficiency when assessing collaborative partnerships between industry and public research organizations. This standout book bridges the gap between theoretical research and legal practice by providing a research-based applied perspective on university-industry collaborations in drug age 4 of cover. . 606 $aIntellectual property$zUnited States 615 0$aIntellectual property 676 $a346.73048 700 $aYu$b Helen$01248041 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910154921903321 996 $aAchieving proof of concept in drug discovery and development$92892907 997 $aUNINA